Ibrutinib Plus Lenalidomide and Rituximab Shows Promise in R/R MCL

At December’s American Society of Hematology (ASH) virtual meeting, data from the PHILEMON phase II trial were presented, which evaluated a regimen of ibrutinib, lenalidomide, and rituximab in patients with relapsed/refractory mantle cell lymphoma.

In this video courtesy of VJHemOnc, study author Mats Jerkeman, MD, of Lund University Cancer Centre in Sweden, discusses the results of the trial.

Following is a transcript of his remarks:

The MCL6 or PHILEMON trial is a similar type of trial [to the VALERIA study] actually, with a similar combination, but with ibrutinib instead of venetoclax. So this was the first study that studied this combination with R² ibrutinib for relapsed refractory mantle cell lymphoma.

And there are 50 patients enrolled in this study, and at this year’s ASH, we presented a longer follow-up with the patients. And we see that we can establish a median progression-free survival which was 19 months.

So it’s quite comparable to ibrutinib alone. We could also see that patients with TP53 mutation and other high-risk features seem to have a similar outcome as patients without these characteristics.

So we still think that this may be a treatment option for high-risk mantle cell lymphoma at relapse. And we can also show that pre-treatment quality of life seem to be prognostic in this population. So patients with lower level of role functioning and emotional functioning had a worse prognosis. And also patients with more pain at baseline seemed to have worse prognosis.